(Q51704334)

10 April 2018

review article

1 reference

title

Current respiratory syncytial virus prevention strategies in high-risk infants. (English)

1 reference

10 April 2018

author name string

Leonard E Weisman

series ordinal

1

1 reference

10 April 2018

publication date

1 October 2002

1 reference

10 April 2018

published in

Pediatrics International

1 reference

10 April 2018

volume

44

1 reference

10 April 2018

issue

5

1 reference

10 April 2018

page(s)

475-480

1 reference

10 April 2018

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Respiratory syncytial virus and reactive airway disease. New developments prompt a new review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Neural mechanisms of respiratory syncytial virus-induced inflammation and prevention of respiratory syncytial virus sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Birth weight and hospital readmission of infants born prematurely

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

The effects of housing on the health of preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Rehospitalization for respiratory syncytial virus among premature infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Recovery of cytopathogenic agent from chimpanzees with coryza

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1442-200X.2002.01613.X

10.1046/J.1442-200X.2002.01613.X

21 January 2018

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018